SAFETY SYSTEM HOSE
    3.
    发明申请
    SAFETY SYSTEM HOSE 失效
    安全系统软管

    公开(公告)号:US20070289630A1

    公开(公告)日:2007-12-20

    申请号:US11849445

    申请日:2007-09-04

    申请人: Richard Boyd

    发明人: Richard Boyd

    IPC分类号: F16K13/08

    摘要: A safety system for a fluid conduit having: a hose; a first housing connected to the hose with an internal cavity having a first connection point and a first check ball opening cavity; a second housing connected to the hose with an internal cavity having a second connection point and a second check ball opening cavity; a perforated retention tube positioned longitudinally within the hose and in communication with the first connection point and the second connection point; a first check device contained within the first check ball opening cavity and interposed between the perforated retention tube and the first check ball opening cavity; and optionally a second check device contained within the second check ball opening cavity and interposed between the perforated retention tube and the second check ball opening cavity.

    摘要翻译: 一种用于流体导管的安全系统,具有:软管; 连接到软管的第一壳体,具有第一连接点和第一止回球开口腔的内腔; 连接到所述软管的第二壳体,具有第二连接点和第二止回球开口腔的内腔; 穿孔保持管纵向定位在软管内并与第一连接点和第二连接点连通; 所述第一检查装置包含在所述第一止回球开口腔内并且插入所述穿孔保持管和所述第一止回球开口腔之间; 以及可选地包含在第二止回球打开腔内的第二检查装置,并且插入穿孔保持管和第二止回球开口腔之间。

    Tolerance to Graft Prior to Thymic Reactivation
    4.
    发明申请
    Tolerance to Graft Prior to Thymic Reactivation 审中-公开
    在胸腺重新激活之前对移植物的耐受性

    公开(公告)号:US20070274946A1

    公开(公告)日:2007-11-29

    申请号:US10553608

    申请日:2004-04-19

    摘要: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue, and/or cells, by disrupting sex steroid signaling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signaling in the patient, is interrupted or ablated by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

    摘要翻译: 本公开提供了通过破坏患者中的性类固醇信号传导来诱导受体中器官,组织和/或细胞的错配移植物的耐受性的方法,其中改善骨髓和其他免疫细胞功能而不在 ,或同时进行胸腺再生。 在一些实施方案中,通过施用LHRH激动剂,LHRH拮抗剂,抗LHRH受体抗体,抗LHRH疫苗,抗雄激素,抗雌激素,选择性雌激素受体调节剂(SERMs),患者中的性别类固醇信号传导被中断或消融 ),选择性雄激素受体调节剂(SARM),选择性孕酮应答调节剂(SPRM),ERD,芳香酶抑制剂或其各种组合。

    Safety system hose
    5.
    发明申请
    Safety system hose 失效
    安全系统软管

    公开(公告)号:US20070039647A1

    公开(公告)日:2007-02-22

    申请号:US11207500

    申请日:2005-08-19

    申请人: Richard Boyd

    发明人: Richard Boyd

    IPC分类号: F16K17/36

    摘要: A safety system for a fluid conduit having: a hose; a first housing connected to the hose with an internal cavity having a first connection point and a first check ball opening cavity; a second housing connected to the hose with an internal cavity having a second connection point and a second check ball opening cavity; a perforated retention tube positioned longitudinally within the hose and in communication with the first connection point and the second connection point; a first check device contained within the first check ball opening cavity and interposed between the perforated retention tube and the first check ball opening cavity; and a second check device contained within the second check ball opening cavity and interposed between the perforated retention tube and the second check ball opening cavity.

    摘要翻译: 一种用于流体导管的安全系统,具有:软管; 连接到软管的第一壳体,具有第一连接点和第一止回球开口腔的内腔; 连接到所述软管的第二壳体,具有第二连接点和第二止回球开口腔的内腔; 穿孔保持管纵向定位在软管内并与第一连接点和第二连接点连通; 所述第一检查装置包含在所述第一止回球开口腔内并且插入所述穿孔保持管和所述第一止回球开口腔之间; 以及第二检查装置,其包含在所述第二止回球开口腔内并且插入在所述穿孔保持管和所述第二止回球开口腔之间。

    Apparatus and method to guarantee unique connection tags across resets in a connection protocol
    7.
    发明申请
    Apparatus and method to guarantee unique connection tags across resets in a connection protocol 审中-公开
    用于在连接协议中的复位之间保证唯一连接标签的装置和方法

    公开(公告)号:US20070005819A1

    公开(公告)日:2007-01-04

    申请号:US11170855

    申请日:2005-06-30

    IPC分类号: G06F3/00

    CPC分类号: G06F13/387

    摘要: A method and apparatus to guarantee unique connection tags across resets in a connection protocol. In one embodiment, the methods include the update of a reset counter following a system reset. In one embodiment, once updated, a controller, such as, for example, an input/output (I/O) controller, may receive a response from a target device to an I/O request that was issued to the target device prior to system reset. In one embodiment, the I/O controller may determine a reset counter value associated with the received response. If the received response includes a reset counter value that does not match a local reset counter held by the I/O controller, the I/O controller may disregard the received response. Other embodiments are described and claimed.

    摘要翻译: 一种保证连接协议中复位的唯一连接标签的方法和装置。 在一个实施例中,所述方法包括在系统复位之后更新复位计数器。 在一个实施例中,一旦更新,诸如输入/输出(I / O)控制器的控制器可以在目标设备之前发送到目标设备的I / O请求的响应 系统复位。 在一个实施例中,I / O控制器可以确定与所接收的响应相关联的复位计数器值。 如果接收到的响应包括与I / O控制器保持的本地复位计数器不匹配的复位计数器值,则I / O控制器可能会忽略接收到的响应。 描述和要求保护其他实施例。

    Diagnostic indicator of thymic function
    8.
    发明申请
    Diagnostic indicator of thymic function 审中-公开
    胸腺功能诊断指标

    公开(公告)号:US20050215479A1

    公开(公告)日:2005-09-29

    申请号:US10418953

    申请日:2003-04-18

    CPC分类号: G01N33/743

    摘要: The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In one embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's blood stream is observed. In another embodiment, the level of new T cells is monitored. An early response, such as within hours or days of the ablation, indicates that the patient's thymus is disposed to regeneration through sex steroid ablation.

    摘要翻译: 本公开提供了一种用于确定患者的免疫系统是否可以通过刺激胸腺功能而被修改的方法。 在一个实施方案中,在患者中消化性类固醇,并监测所产生的胸腺因子。 特别地,观察到患者血液中的这些因素的水平。 在另一个实施方案中,监测新T细胞的水平。 早期反应,如消融后数小时或数天内,表明患者的胸腺通过性类固醇消融进行再生。

    Hematopoietic stem cell gene therapy
    9.
    发明申请
    Hematopoietic stem cell gene therapy 审中-公开
    造血干细胞基因治疗

    公开(公告)号:US20050020524A1

    公开(公告)日:2005-01-27

    申请号:US10748831

    申请日:2003-12-30

    申请人: Richard Boyd

    发明人: Richard Boyd

    IPC分类号: A61K48/00

    摘要: The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenitor cells. The cells are genetically modified to provide a gene that is expressed in these cells and their progeny after differentiation. In one embodiment the cells contain a gene or gene fragment that confers to the cells resistance to HIV infection and/or replication. The cells are administered to a patient in conjunction with treatment to reactivate the patient's thymus. The cells may be autologous, syngeneic, allogeneic or xenogeneic, as tolerance to foreign cells is created in the patient during reactivation of the thymus. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In another embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

    摘要翻译: 本公开提供了利用造血干细胞,淋巴祖细胞和/或骨髓祖细胞的基因治疗方法。 细胞被遗传修饰以提供在这些细胞中表达的基因及其在分化后的后代。 在一个实施方案中,细胞含有赋予细胞对HIV感染和/或复制抗性的基因或基因片段。 将细胞与治疗一起施用于患者以重新激活患者的胸腺。 细胞可以是自体的,同基因的,同种异体的或异种的,因为在重新激活胸腺期间在患者体内产生对外来细胞的耐受性。 在一个实施方案中,造血干细胞是CD34 +。 患者的胸腺通过破坏性类固醇介导的胸腺信号传导而重新激活。 在另一个实施方案中,通过施用LHRH激动剂,LHRH拮抗剂,抗LHRH受体抗体,抗LHRH疫苗或其组合来产生该破坏。

    Diagnostic indicator of thymic function
    10.
    发明申请

    公开(公告)号:US20050042679A1

    公开(公告)日:2005-02-24

    申请号:US10749120

    申请日:2003-12-30

    IPC分类号: G01N33/53

    摘要: The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In one embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's blood stream is observed. In another embodiment, the level of new T cells is monitored. An early response, such as within hours or days of the ablation, indicates that the patient's thymus is disposed to regeneration through sex steroid ablation.